AstraZeneca Annual Report and Form 20-F Information 2011

  • $33.6bn

    Sales down 2% at CER to $33,591 million ($33,269 million in 2010)

  • $13.2bn

    Core operating profit down 4% at CER to $13,167 million ($13,603 million in 2010)

  • $12.8bn

    Reported operating profit up 10% at CER to $12,795 million ($11,494 million in 2010)

  • $7.28

    Core EPS for the full year increased by 7% at CER to $7.28 ($6.71 in 2010)

  • $7.33

    Reported EPS for the full year increased by 29% at CER to $7.33 ($5.60 in 2010)

  • $9.37bn

    Net cash shareholder distributions increased by 71% to $9,370 million including net share repurchases of $5.6 billion


null null null null null null null null null null null null null null null null null null